share_log

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $13 Price Target

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $13 Price Target

HC Wainwright & Co.重申买入Coherus BioSciences,维持13美元的目标股价
Benzinga ·  2023/12/07 06:26

HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $13 price target.

HC Wainwright & Co. 分析师曹道格拉斯重申了Coherus BioSciences(纳斯达克股票代码:CHRS)的买入并维持13美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发